Affection of cardiovascular system in antiphospholipid syndrome with non-bacterial thrombotic endocarditis


Cite item

Full Text

Abstract

Aim. To study characteristics of cardiovascular affection in antiphospholipid syndrome (APS) with nonbacterial thrombotic endocarditis (NBTE). Material and methods. The trial included 28 patients with APS and NBTE (26 females, mean age 44 ± 13 years). Primary APS was diagnosed in 21 patients, secondary APS associated with systemic lupus erythematosus - in 7 patients. Transthoracic echocardiography was performed in all the patients, transesophageal echocardiography - in 86% of them. Statistic processing was made with logistic regression analysis. Results. All the patients had structural valvular changes: leaflet thickening, sclerosis, vegetations, focuses of calcinosis and valvular dysfunction. Vegetations located on mitral and aortic valves in 64% and occurred on damaged heart valves in 36% patients. An important problem in APS with NBTE was systemic embolism (54%), especially with involvement of central nervous system. Logistic regression revealed association of NBTE with structural changes of aortic and mitral valves, myocardial focal fibrosis and valvular insufficiency. Conclusion. APS with NBTE is characterized by absolute predominance of valvular heart lesion with vegetations location on the left heart valves and high risk of embolic complications.

About the authors

A A Demin

Новосибирский государственный медицинский университет МЗ и CP РФ

N N Chapaeva

Новосибирский государственный медицинский университет МЗ и CP РФ

M A Trifonova

Новосибирский государственный медицинский университет МЗ и CP РФ

References

  1. Ros J. О., O'Callaghan A. S., Vilardell М. Thrombotic manifestations in the antiphospholipid syndrome. In: Asherson R. A., Cervera R., Piette J.-C., Shoenfeld Y., eds. The antiphospholipid syndrome: autoimmune thormbosis. Amsterdam: Elsevier; 2002. 145-154.
  2. Демин А. А. Антифосфолипидный синдром. Журн. клин. и экспер. мед. 2005; 1-2: 12-23.
  3. Насонов Е. Л. Антифосфолипидный синдром. М.: Литтерра; 2004.
  4. Чапаева Н. Н., Ефремов А. В., Демин А. А., Непомнящих Г. И. Антифосфолипидный синдром. Новосибирск: СО РАМН; 2003.
  5. Khamashta М. A., ed. Hughes syndrome: Antiphospholipid syndrome. 2-nd ed. London: Springer-Verlag; 2006.
  6. Amigo M. C. The heart and APS. Clin. Rev. Allergy Immunol. 2007; 32 (2): 178-183.
  7. Tenedios F., Erkan D., Lockshin M. D. Cardiac involvement in the antiphospholipid syndrome. Lupus 2005; 14 (9): 691-696.
  8. Soltész P., Szekanecz Z., Kiss Е., Shoenfeld Y. Cardiac manifestations in antiphospholipid syndrome. Autoimmun. Rev. 2007; 6 (6): 379-386.
  9. Решетняк Т. M., Котелъникова Г. П., Фомичева О. А. и др. Кардиологические аспекты антифосфолипидного синдрома. Часть I. Клапанные поражения сердца при первичном и вторичном антифосфолипидном синдроме и системной красной волчанке. Кардиология 2002; 7: 38-43.
  10. Eiken P. W., Edwards W. D., Tazellar Н. D. et al. Surgical pathology of nonbacterial thrombotic endocarditis in 30 patients, 1985-2000. Mayo Clin. Proc. 2001; 76: 1204-1212.
  11. Llenas-Garcia J., Guerra-Vales J. M., Montes-Moreno S. et al. Nonbacterial thrombotic endocarditis: clinicopathologic study of a necropsy series. Rev. Esp. Cardiol. 2007; 60 (5): 493-500.
  12. Krause I., Lev S., Fraser A. et al. Close association between valvular heart disease and central nervous system manifestations in the antiphospholipid syndrome. Ann. Rheum. Dis. 2005; 64 (10): 1490-1493.
  13. Levine S. R., Brey R. L., Joseph C. L. M., Havstad S. Risk of recurrent thromboembolic events in patients with focal cerebral ischemia and antiphospholipid antibodies. Stroke 1992; 18 (1): 29-32.

Copyright (c) 2008 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies